There are eight firms with a “buy” rating and three analysts with a “sell” rating. There is a one-year price target of $16.75, according to the report.
JPMorgan Chase & Co., reiterated the “neutral” rating with a price target at $14.67 earlier this week. Last week, Beaufort Securities reiterated the “sell” rating.
This past Monday, Smith & Nephew’s Julie Brown sold 4,227 shares on the open market at $17 per share for a total transaction reaching $71,869.19.
More articles on surgery:
5 key notes on delayed spine surgery after traumatic central cord syndrome
Power vs. manual tools for scoliosis surgery—5 key notes
5 things to know about adult spinal deformity surgical revision rates
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
